Q2 & H1FY27 call transcript: management reaffirms FY27 growth guidance
Senores Pharmaceuticals shared the transcript of its Q2 & H1FY27 earnings call held on October 29, 2026.
By ScoutQuest · · 2 min read
- Q2 Revenue
- INR192 crores
- Q2 EBITDA / PAT
- EBITDA INR58 crores, PAT INR36.6 crores
- FY27 Guidance
- 30% to 40% revenue growth and 50% to 60% PAT growth
Senores Pharmaceuticals has shared the transcript of its Q2 & H1FY27 earnings conference call held on October 29, 2026. The call was addressed by Promoter and Managing Director Swapnil Shah, Chairman Sanjay Majmudar, and Whole-time Director and Chief Financial Officer Deval Shah.
Q2 FY27 numbers
- Revenue from operations: INR192 crores
- EBITDA: INR58 crores
- Profit after tax: INR36.6 crores
- Management described this as the company's highest-ever quarterly revenue and EBITDA.
H1 FY27 numbers
- Revenue: INR372.5 crores
- Profit after tax: INR67 crores
Cash generation
- Operating cash flow in H1 FY27: INR38 crores
- Management said working capital days and receivable days improved, which supported stronger operating cash flows.
Guidance given on the call
- FY27: revenue growth of 30% to 40%, with corresponding PAT growth of 50% to 60%
- Management said H2 has historically been stronger than H1 and expects that trend to continue in FY27, helped by upcoming launches and better commercialisation.
- The Q2 and H1 results include the initial setup and operating costs of Amerisyn and Zoraya, which did not contribute revenue in this period. Both are expected to start contributing from H2 FY27, with a more meaningful ramp-up anticipated from FY28 onwards.
Products and markets
- Management said the ANDA portfolio has nearly doubled over the year and that a part of it is already commercialised; an ANDA approval received in the quarter is slated for launch in Q3 FY27.
- The regulated market, emerging market and CMO/CDMO businesses all grew during the quarter, according to management, and the emerging market business has turned cash positive.
- R&D spending is being directed at complex and specialty products, and capacity is being added, including a pre-filled syringe line aimed at GLP-1 and other products.
- In India, the field force and market reach for the branded generic and critical care business have been expanded.
Manufacturing
- Manufacturing at the recently acquired US FDA-approved Apnar plant is scaling up and is in line with internal expectations, management said.
- A minor procedural 483 observation was received at a recent inspection of the Apnar facility; management said full-scale operations and further expansion there are planned over the coming period.
Points to keep in mind
- The figures are management's commentary on the quarter and half year as stated on the call.
- The guidance is a management expectation; the call itself notes that forward-looking statements involve risks and uncertainties and are not guarantees of future performance.
- The transcript states that where there is any discrepancy, the audio recording uploaded on the stock exchange on 29th October 2026 will prevail.
Also from Senores Pharmaceuticals
Subsidiary's Mehsana facility awarded PIC/S GMP certification by Ukraine's SMDC
17 Nov 2026
Senores Pharmaceuticals files audio recording of Q2 & H1FY27 earnings conference call held October 29, 2026
29 Oct 2026
Monitoring agency report: nil deviation from IPO objects, after objects and timelines were revised
29 Oct 2026
More numbers
- Q2 FY27 revenue from operationsINR192 crores
- Q2 FY27 EBITDAINR58 crores
- Q2 FY27 profit after taxINR36.6 crores
- H1 FY27 revenueINR372.5 crores
- H1 FY27 profit after taxINR67 crores
- H1 FY27 operating cash flowINR38 crores
- FY27 revenue growth guidance30% to 40%
- FY27 PAT growth guidance50% to 60%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.